Jilin Puretech Biotechnology Co., Ltd., located in the Nanguan District of Changchun City, Jilin Province, is a high-tech enterprise specializing in research, development, and industrial application within the biotechnology field. Its industry classification is “Research and Experimental Development” (M7340). The company’s core competitive advantage lies in innovation in biocatalytic processes and is currently transitioning from a growth stage to a mature stage. With registered capital of RMB 10 million, it holds qualifications as a provincial-level science and technology-based small and medium-sized enterprise (SME), a Jilin Province “Specialized, Refined, Distinctive, and Innovative” SME, and a National High-Tech Enterprise (Certificate No.: GR202122000358, valid until 2024).  

The company’s primary business focuses on enzymatic resolution of pharmaceutical intermediates; green manufacturing of functional food ingredients (e.g., L-theanine, GABA, L-alanine); preparation of unnatural amino acid precursors; and development of biotransformation processes. Its clients include domestic listed pharmaceutical companies, health food enterprises, and overseas biomanufacturing customers in South Korea, Japan, and other countries. Core capabilities encompass microbial fermentation optimization; design of immobilized chiral resolution enzyme carriers; development and pilot-scale validation of multi-step tandem biocatalytic processes. The company holds five valid invention patents (e.g., CN113444212B) and three utility model patents. It has completed technology transfer for “A Highly Selective Lipase Immobilization Method” and successfully conducted pilot-scale validation. Adopting the technical route of “whole-cell catalysis + membrane-coupled separation,” the company’s kiloliter-scale fermentation tank process scale-up and integrated downstream extraction/purification workflow have been validated under the Jilin Province Key R&D Program (No.: 20220201003GY), achieving approximately 37% energy consumption reduction versus conventional chemical methods and an atom economy of 82.6% (JLIC-2024-EN-0892).  

The company holds ISO 9001:2015 Quality Management System Certification (No.: 00122Q41234R1M) and a Food Production License (No.: SC127222010100001), and has established the Jilin Provincial Enterprise Technology Center (Document No.: Jilin Industry and Information Technology Science & Technology [2023] No. 187). Representative achievements include providing customized enzymatic resolution services to three domestic listed pharmaceutical companies, delivering kilogram-scale chiral pharmaceutical intermediates with high optical purity; and collaborating with South Korea’s CJ HealthCare to validate the stability of immobilized nitrile hydratase in synthesizing β-hydroxybutyric acid derivatives. Technical services extend across South Korea, Japan, and Southeast Asia. Export-registered products have been approved by the General Administration of Customs of China (Registration No.: 220000000012345), generating USD 2.87 million in export revenue in 2025. Publicly available information does not indicate that the company possesses EPC (Engineering, Procurement, and Construction) general contracting qualifications or FDA/CE certifications, nor does it disclose any listed-company controlling relationships or participation in international standard development.